Division of Allergy Immunology and Dermatology, Montreal Children's Hospital, Montreal, Quebec, Canada.
St John's Institute of Dermatology, Guy's Hospital, London, United Kingdom.
J Allergy Clin Immunol Pract. 2018 Jul-Aug;6(4):1152-1161. doi: 10.1016/j.jaip.2018.02.015. Epub 2018 Mar 14.
There are substantial knowledge gaps related to diagnosis and management of pediatric cases of chronic urticaria, and in particular chronic spontaneous urticaria (CSU). In this article we aimed to review the diagnosis and management of chronic urticaria in children and CSU in particular. We conducted a systematic review of articles published in English and French on pediatric CSU management in the last 10 years. We included experimental studies (eg, randomized controlled trials), other experimental designs (eg, nonrandomized methods of assignment, controlled before-after studies, and interrupted time series), and observational studies (eg, prospective or retrospective cohort studies, cross-sectional studies, case-control studies, and case reports). Our findings highlight the efficacy of second-generation antihistamines for the treatment of CSU in children and supports the use of omalizumab for more severe cases. However, our study also reveals severe knowledge gaps related to the best management strategy in children with more severe/refractory cases of CSU. Future studies are required to establish the beneficial effect of high doses of second-generation antihistamines as well as the effectiveness and safety of omalizumab and other biologics in young children.
有关儿童慢性荨麻疹(尤其是慢性自发性荨麻疹)的诊断和治疗方面存在大量知识空白。本文旨在回顾儿童慢性荨麻疹,特别是慢性自发性荨麻疹的诊断和治疗。我们对过去 10 年发表的关于儿童慢性自发性荨麻疹管理的英文和法文文章进行了系统回顾。我们纳入了实验性研究(如随机对照试验)、其他实验性设计(如非随机分组方法、对照前后研究和时间序列中断)和观察性研究(如前瞻性或回顾性队列研究、横断面研究、病例对照研究和病例报告)。我们的研究结果强调了第二代抗组胺药治疗儿童慢性自发性荨麻疹的疗效,并支持使用奥马珠单抗治疗更严重的病例。然而,我们的研究还揭示了与更严重/难治性慢性自发性荨麻疹患儿最佳治疗策略相关的严重知识空白。需要进一步的研究来确定高剂量第二代抗组胺药的有益效果,以及奥马珠单抗和其他生物制剂在幼儿中的有效性和安全性。